This statement by Dr Recknor is very bothersome:
Post# of 144932
50. This means that the studies will experience a gap in monitoring and may not be useable for FDA approval.
I can't imagine what that would do to future investors interest in putting money at risk.
The Brazil trials must be positive.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)